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Vascular endothelial growth factor and its recep-
tors, FLK1/KDR and FLT1, are key regulators
of angiogenesis. Unlike FLK1/KDR, the role of
FLT1 has remained elusive. FLT1 is produced as
soluble (sFLT1) and full-length isoforms. Here, we
show that pericytes from multiple tissues produce
sFLT1. To define the biologic role of sFLT1, we
chose the glomerular microvasculature as a model
system. Deletion of Flt1 from specialized glomerular
pericytes, known as podocytes, causes reorga-
nization of their cytoskeleton with massive protein-
uria and kidney failure, characteristic features of
nephrotic syndrome in humans. The kinase-defi-
cient allele of Flt1 rescues this phenotype, demon-
strating dispensability of the full-length isoform.
Using cell imaging, proteomics, and lipidomics, we
show that sFLT1 binds to the glycosphingolipid
GM3 in lipid rafts on the surface of podocytes,
promoting adhesion and rapid actin reorganization.
sFLT1 also regulates pericyte function in vessels
outside of the kidney. Our findings demonstrate
an autocrine function for sFLT1 to control pericyte
behavior.384 Cell 151, 384–399, October 12, 2012 ª2012 Elsevier Inc.INTRODUCTION
Vascular endothelial growth factor (VEGF) is a major regulator
of developmental and pathologic angiogenesis. There are two
main cognate receptor tyrosine kinases for VEGF: FLK1/KDR
(VEGFR2) and FLT1 (VEGFR1). The classically recognized func-
tions of VEGF, including regulation of endothelial cell migration,
proliferation, and differentiation, are mediated by FLK1/KDR. In
contrast, the role of FLT1 is not as well understood. Two major
splice variants of the FLT1 gene encode the full-length trans-
membrane receptor and a soluble, secreted, truncated receptor
(soluble FLT1 [sFLT1]) (Shibuya, 2001); the soluble FLT1 mes-
senger RNA (mRNA) is translated into a protein consisting of
six Ig repeats and a unique C terminus that retains the ligand-
binding domain but lacks the transmembrane and C-terminal
tyrosine kinase domains.
sFLT1 is capable of binding all isoforms of VEGF, inhibiting
their proangiogenic function. Conventional knockout of the
Flt1 gene in mice results in a lethal vascular phenotype charac-
terized by endothelial cell overgrowth, suggestive of enhanced
VEGF activity (Fong et al., 1995). In contrast, mice carrying two
modified Flt1 alleles lacking the cytoplasmic tyrosine kinase
signaling domain but retaining the ability to express the
soluble Flt1 isoform are viable with only mild adult phenotypes
(Hiratsuka et al., 1998; Niida et al., 2005; Sawano et al., 2001).
Together, these results suggest that signaling by FLT1 is non-
essential and support a primary role for FLT1 and sFLT1 as
decoy receptors, limiting the availability of VEGF to signal
through FLK1/KDR.
In this regard, elevated circulating levels of sFLT1 are associ-
ated with pre-eclampsia and characteristic abnormalities in the
microvasculature in the kidney (Maynard et al., 2003). Thus,
along with its actions to regulate systemic angiogenesis, VEGF
and its receptors play a critical role in regulating the development
and function of the glomerular filtration barrier in the kidney
(Eremina et al., 2003, 2008). The glomerulus is a specialized
microvascular bed that is lined by fenestrated, highly flattened
endothelial cells. Podocytes function as vasculature support
cells or specialized pericytes, extending primary microtubular-
based processes and secondary actin-based foot processes
around the underlying glomerular capillaries and serving as the
main source of VEGF in the glomerulus.
Unexpectedly, we find that podocytes and other perivascular
cells from a number of vascular regions produce sFLT1. Thus,
we wondered what biologic role(s) sFLT1 plays in pericytes, first
focusing on glomerular podocytes as a model system.
RESULTS
Differentiated Pericytes and Perivascular Cells
Produce sFlt1
sFLT1 is deposited around mature vessels, suggesting local
production occurs away from the circulatory side (Sela et al.,
2008, 2011). We screened for expression of sFLT1 by quantita-
tive PCR (qPCR) in a number of pericyte and perivascular cell
lines, as well as endothelial cells (Figure 1A). Pericytes and peri-
vascular cells from the kidney, embryo (10T1/2), retina (Fig-
ure 1A), brain, placenta, and liver (data not shown) express full-
length and sFLT1. To define the in vivo function of FLT1
produced by pericytes, we focused on the glomerular microvas-
culature and podocytes as a well-characterized vascular bed.
Analysis of sFlt1 as compared to full-length Flt1 from fluores-
cence-activated cell sorted (FACS sorted) primary mouse podo-
cytes confirms that sFlt1 is themajor isoform produced by podo-
cytes (Figure 1B) (Sison et al., 2010). Moreover, Flt1 is the only
VEGF receptor with detectable expression in podocytes, where
it is expressed beginning at 3 weeks and peaking at 6 weeks of
age (Figure 1B; Sison et al., 2010). Using immunogold electron
microscopy, we find that the Flt1 protein is primarily located at
the basal aspect of podocyte foot processes, adjacent to the
slit diaphragm (Figure 1C) and in endosomes (data not shown).
Podocyte-Selective Deletion of Flt1 Results
in Cytoskeletal Reorganization and Proteinuria
To determine the function of Flt1 in podocytes in vivo, mice
carrying a floxed Flt1 allele were bred to mice expressing Cre
recombinase under control of the podocyte-specific Nphs1
promoter (Figure 1D; Eremina et al., 2003). In mice carrying
two floxed Flt1 alleles and the Cre transgene (Nphs1-Cre+
Flt1flox/flox), proteinuria could be detected at 4 weeks of age
(2.3-fold increase over control) that rapidly increases during
subsequent weeks (10-fold increase at 8 weeks) (Figure 1E). At
3 weeks of age, before the onset of proteinuria, electron micro-
graphs (EMs) of mutant mice are indistinguishable from controls,
demonstrating proper development and formation of foot pro-cesses and slit diaphragms (data not shown). At 6 weeks,
histologic analysis shows minimal structural changes in the
glomerulus by light microscopy but obvious protein casts in
tubules (Figure 1F). However, EMs show profound reorganiza-
tion of podocyte architecture with flattening of foot processes
(Figure 1G). Upon aging, glomerular injury progresses with struc-
tural changes evident by 8 weeks of age. By 12 weeks, there is
evidence of neoangiogenesis, with abnormal blood vessels ob-
served in the urinary space of a small number (<5%) of glomeruli
(Figure 1H), but this was a minor feature compared to podocyte
defects, indicating a predominant role for direct actions of Flt1
to maintain normal pericyte function.
A Kinase-Deficient Flt1 Allele Rescues the Phenotype
To determine whether the glomerular defects resulted from
loss of the signaling function of Flt1, we used TK mutant mice
(Flt1TK/TK) lacking the cytoplasmic domain and its tyrosine resi-
dues, but retaining the entire transmembrane and ligand-binding
domains and so capable of producing the sFlt1 protein. Flt1TK/TK
mice do not develop proteinuria or glomerular dysfunction out to
1.5 years of age, demonstrating that elimination of Flt1 signal-
ing does not significantly alter podocyte function (Figures 2A
and 2B; Table S1 available online). By contrast, 98% of mice
lacking both full-length and soluble Flt1 proteins from podo-
cytes (Nphs1-Cre+Flt1flox/flox) develop proteinuria and glomerular
pathology by 6 weeks of age, as shown in Figures 1E and 2B and
Table S1. To determine whether the selective presence of the
kinase-deficient, truncated Flt1 in podocytes could rescue the
phenotype, we generatedmice carrying one TK allele, one floxed
Flt1 allele, and the Nphs1-Cre transgene (Nphs1-Cre+Flt1flox/TK).
These mice can express full-length Flt1 as well as sFlt1 in all
tissues except podocytes, in which the floxed allele is inacti-
vated, leaving only Flt1TK. Out of 33 animals that were examined,
the majority (n = 25) do not develop proteinuria or other evi-
dence of kidney pathology, indicating that a single Flt1TK allele
can rescue the kidney phenotype caused by deletion of
Flt1 from podocytes (Table S1). We isolated glomeruli from
a group of Nphs1-Cre+ Flt1flox/TK mice with (n = 3) or without
(n = 12) abnormal proteinuria and measured sFlt1 expression.
Mice with proteinuria expressed lower levels of sFlt1 (Figure 2C)
compared with rescued Cre+Flt1flox/TK mice, suggesting a
threshold level of sFlt1 is required to maintain normal podocyte
morphology.
sFLT1 Promotes Cell Adhesion and Podocyte
Cytoskeleton Reorganization
Our in vivo data suggest that elimination of sFlt1 in podocytes
causes profound changes in structure and function, indicating
a critical and unexpected function for sFlt1 in these cells. To
explore the underlying mechanism, we assessed responses of
human podocytes exposed to recombinant sFLT1. Podocytes
adhere to native sFLT1 or sFLT1-Fc proteins with similar affinity
as fibronectin, a strong stimulus of podocyte adhesion (Borza
et al., 2008) (Figure 3A). Furthermore, there is a clear dose-
dependence of the adhesive response to sFLT1 (Figure 3B). In
contrast, podocytes do not attach to immunoglobulin G (IgG),
sFLK1/KDR-Fc, or soluble platelet-derived growth factor re-
ceptor b-Fc (Figures 3A and 3B), confirming specificity ofCell 151, 384–399, October 12, 2012 ª2012 Elsevier Inc. 385
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Figure 1. Deletion of Flt1 from Podocytes Results in Foot Process Effacement and Proteinuria
(A) Similar to HUVECs, human perivascular cells and pericytes, including RPE cells, podocytes (Pod37) and 10T1/2 cells express full-length and soluble FLT1
as determined by qPCR. mRNA levels were normalized to HPRT. Changes are shown as fold change compared to RPE expression (1) for each gene. Bars
represent SEM.
(B) Mouse podocytes express sFlt1 (measured by qPCR) beginning at 3 weeks of age and increasing until 6 weeks. Primary podocytes expressing a CFP+
transgene were isolated frommouse glomeruli. The CFP fraction represents endothelial andmesangial cells isolated from the glomerulus. Expression levels are
represented as normalized means and SEM.
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reaction. We also monitored cell adhesion via real-time reading
of electrical impedance (Yu et al., 2006). As expected, podocytes
initiate attachment in response to sFLT1 more rapidly and with
greater affinity than to sFLK1/KDR (Figure S1A). Adhesion of
podocytes to fibronectin is cation dependent and mediated by
aVb3 integrins (Borza et al., 2008). While attachment of podo-
cytes to sFLT1 is also inhibited by EDTA and EGTA, it is not
affected by specific blocking antibodies to integrins (Figures
S1B and S1C). Further, pretreatment with heparin has no effect
on podocyte binding to fibronectin, but completely abolishes
binding to sFLT1 in a dose-dependent manner (Figure 3C), sug-
gesting a different mechanism of adhesion between the two
substrates.
Finally, binding of podocytes to sFLT1 is accompanied by
rapid and striking reorganization of the cytoskeleton with forma-
tion of filopodial or foot-process-like structures within minutes
(Figure 3D).sFLT1 Binds to the Cell Surface followed by Rapid
Endocytosis
At 0C, sFLT1 binds to the surface of podocytes in a fine punc-
tate pattern (Figures 3E and S2A). Patching of sFLT1 on the
cell surface is abolished by pretreatment of podocytes with
heparin (Figure S2B). As before, there is no binding of sFLK1/
KDR to podocytes (Figure S2A). Premixture with VEGF (bio-
tinylated VEGF-165) does not affect sFLT1 binding to podocytes
(Figure S2C). Also, in the absence of endogenous or exogenous
VEGF, sFLT1 binding is not altered (data not shown), indicating
this association is independent from the native ligand. Con-
versely, although there is no direct VEGF binding to the podocyte
(data not shown), when VEGF ismixedwith sFLT1 in themedium,
we observed VEGF deposition on the cell surface at the sites of
sFLT1 microdomains (Figure S2C) as well as VEGF endocytosis
(data not shown), raising the possibility that sFLT1 might pro-
mote cellular uptake of VEGF.
Upon thermoshifting to 33C, dynamic ‘‘pooling’’ or fusion of
sFLT1 patches can be observed in real-time (Movie S1) followed
by formation of distinct compact punctae (Figures 3E and S2A).
The coalescence of punctae does not occur following treatment
with dynasore, an inhibitor of dynamin (Figure S3A). At the
plasma membrane, some of these punctae colocalize with flotil-
lin and Rab5 (Figure S3B at 0C), which are regulators of
membrane dynamics and vesicle trafficking. Upon thermoshift-
ing (Figure S3B at 33C), the extent of colocalization is increased(C) Immunogold EM staining shows Flt1 (arrowheads) localizes to the base of th
kidneys. GBM, glomerular basement membrane.
(D) Targeting strategy for deletion of Flt1 from podocytes. Triangles, loxP sites.
(E) Loss of Flt1 from podocytes results in proteinuria determined by urine protein-c
and increases rapidly with time. No proteinuria was observed in control mice. (*p
(F) At 4 weeks of age, glomeruli from Nphs1-Cre+Flt1flox/flox mice appear norma
structure is disrupted. A control glomerulus at 6 weeks is shown for comparison
(G) At 6 weeks, podocytes from Nphs1-Cre+Flt1flox/flox mutant mice show striki
normal fp structure (left). Mutant animals exhibit flattening of podocyte foot proce
fenestrations (arrowheads).
(H) Abnormal blood vessel growth is observed in the urinary space of a minority of
the ectopic vessels, which are lined by CD31+ endothelial cells (white arrows).
glomerulus in (F).
See also Table S1.and most evident in endosomes. These sFLT1 punctae also
colocalize with endocytic markers HRS1 and EEA1 (Figures S3A
and S3C) and the endocytic/adaptor protein CIN85 (Figure S3D),
consistent with rapid endocytosis of sFLT1 after binding. Immu-
nogold staining demonstrates that, at 0C, sFLT1 localizes to
discrete patches on the surface of the podocyte, which expand
at 33C, suggesting coalescence of surface microdomains (Fig-
ure 3F). When cells are fixed 30 min after the addition of sFLT1,
we find sFLT1 internalized in endocytic vesicles, and occasion-
ally, immunogold-labeled sFLT1 is concentrated at the sites of
cell-cell contact (Figure 3F).
Mass Spectrometry Analysis to Identify Binding
Partners for sFLT1
Our data demonstrate specific interaction between the podo-
cyte and sFLT1 at the cell surface, inducing adhesion and
modification of the cytoskeleton. To identify sFLT1 binding
partners on the podocyte cell surface, we utilized covalent
crosslinking coupled with mass spectrometry. In a pilot study,
we tested two crosslinkers, bissulfosuccinimidyl suberate (BS3)
and dimethyl adipimate (DMA). Only treatment with BS3 pro-
duced sFLT1 bands at higher molecular weight (Figure S4A),
and thus BS3 was used for the large-scale mass spectrometry
experiments.
sFLT1 and cross-linked proteins were immunoprecipitated
from the lysate and digested with trypsin or chymotrypsin for
mass spectrometry (Figure 4A). Coimmunoprecipitated proteins
were identified and ranked according to mass spectrometry
search scores (Mascot, Figure 4B). Three of the top hits,
ANXA2, ROBO4, and SCARB1, were chosen for further study.
ROBO4 partially colocalizes with sFLT1 in endocytic vesicles,
whereas SCARB1 shows more extensive colocalization with
sFLT1 on the surface of podocytes (Figure S3D). The cyto-
plasmic abundance of ANXA2 precludes membrane localization
with any degree of certainty (data not shown). To determine if any
of these proteins bind sFLT1, we performed coimmunoprecipita-
tion studies but were unable to demonstrate direct interaction
(data not shown), suggesting instead that they reside in a larger
surface membrane complex with sFLT1.
sFLT1 Is Associated with the Lipid Raft
Although the initial goal of the screen was to identify a specific
binding protein for sFLT1, we reasoned that proteins cross-
linked due to their vicinity and abundance should provide usefule foot process (fp) and beneath the slit diaphragm (SD) of podocytes from rat
reatine ratio (U-P/C) that starts at 4 weeks of age inNphs1-Cre+Flt1flox/floxmice
< 0.05; **p < 0.02; ***p < 0.01). Bars represent SEM. See also Table S1.
l. At 6 weeks, protein is visible in the tubules (*), and by 8 weeks, glomerular
.
ng reorganization of cytoskeleton with foot process effacement. Compare to
sses, known as effacement. Endothelium is structurally intact, as evidenced by
glomeruli (<5%) by 12 weeks of age. Red blood cells (black arrow) are visible in
PDGFRb stains the mesangial cells. Compare to normal structure of control
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Figure 2. A Kinase-Deficient, Truncated Flt1 Allele Rescues the
Phenotype
(A) Glomeruli appear normal in Flt1TK/TK mutant mice up to 1.5 years of age
(colored panels), and the ultrastructure of the glomerular barrier appears intact
in transmission electron micrographs (black and white panels). A single TK
allele rescues the podocyte defect in mice carrying one podocyte-specific null
Flt1 flox allele (Cre+Flt1flox/TK). Normal fps are indicated by arrowheads.
(B) U-P/C ratios are not different from wild-type in Flt1TK/TK mice, whereas
Nphs1-Cre+Flt1flox/flox littermates demonstrate elevated proteinuria at 6 weeks
of age. Bars represent SEM.
(C) sFlt1 mRNA levels (determined by qPCR) are lower in the few Nphs1-
Cre+Flt1flox/TK mice that do not exhibit glomerular rescue (high U-P/C ratio),
indicating a threshold level of sFlt1 is required for glomerular integrity.
Measurements performed at 7 weeks of age.
See also Table S1.
388 Cell 151, 384–399, October 12, 2012 ª2012 Elsevier Inc.clues about the molecular environment of sFLT1 at the cell
surface. Of note, several of these proteins are known to localize
to lipid raft microdomains. For example, Ca2+-binding ANXA2
and its S100 subunit proteins have a structural role in the regula-
tion of raft dynamics (Gerke et al., 2005) and SCARB1 is highly
associated with raft microdomains, where it functions in the
cholesterol uptake pathway (Rhainds et al., 2004). These proteo-
mic findings are also consistent with the EM ultrastructural
features of sFLT1-associated membrane patches, suggesting
a raft-like dynamic (Figure 3F). Accordingly, we explored the
association of sFLT1 with these proteins and the lipid raft itself.
SCARB1 and sFLT1 are both isolated in the lipid raft fraction,
defined by detergent resistance (Lingwood and Simons, 2010),
the presence of caveolin-1, and absence of beta integrin (Fig-
ure 4C). Lipid rafts may also be identified by cholera-toxin
B-subunit (CTxB) that binds to the raft ganglioside GM1. sFLT1
and CTxB demonstrate extensive colocalization on the plasma
membrane of podocytes (Figure 4D).
Colocalization studies of sFLT1 with ANXA2 are not feasible,
due to a lack of specific reagents. However, small interfering
RNA (siRNA) knockdown of ANXA2 in podocytes (Fig-
ures S4C–S4E) alters the pattern and distribution of binding of
CTxB and sFLT1 to the cell surface. At 0C, CTxB and sFLT1
binding in the central region of the cells is completely absent
(Figure 4E). Furthermore, ANXA2 knockdown causesmajor alter-
ations in podocyte morphology, which is evident using phase
contrast microscopy (Figures S4D and S4E). Together, these
data suggest that ANXA2 serves as an integral component of
the sFLT1-associated lipid raft surface complexes in podocytes.
sFLT1 Binds Directly to the Lipid Raft GM3 Ganglioside
GM3 is a second glycosphingolipid that is highly enriched in lipid
raft domains, where it interacts with tyrosine kinase growth
factor receptors, such as FLK1/KDR, and facilitates biologic
responses in cells (Chung et al., 2009; Mukherjee et al., 2008).
Given the high degree of sequence and structural conservation
between FLT1 and FLK1/KDR, we reasoned that sFLT1 might
also interact with GM3. Furthermore, the sialic acid moiety of
GM3 exhibits a similar structure and negative charge as heparin,
whereas sFLT1 is highly basic and carries a positive charge
suggestive of electrostatic interactions between these mole-
cules (Figure S5). In keeping with this possibility, heparin com-
pletely abolishes sFLT1 patching on the podocyte cell surface
(Figure S2B). To determine whether GM3 interacts directly with
sFLT1, we mixed purified GM3 with sFLT1-Fc or IgG affinity
beads and determined the amount of GM3 bound to beads by
mass spectrometry using multiple reaction monitoring (MRM).
sFLT1 binds with 20-fold higher affinity to GM3 than IgG control
(Figure 5A), confirming a direct interaction.
Having established the MRM protocol for GM3, which mea-
sures the ionization of the sialic acid group (Figure S6A), we
extended the assay to monitor multiple ganglioside species
simultaneously extracted from podocytes. Because ganglio-
sides are characterized by the unique configuration of their sia-
lated termini, allowing them to be systematically targeted by
MRM, we programmed themass spectrometer to detect 39 spe-
cies of gangliosides. First, we demonstrated that it is possible to
measure each of eight ganglioside types in a mixture of GM1,
GM3, and GD1a standards (Figure S6). We then conducted co-
precipitation assays using sFLT1 and a crude extract of total
gangliosides isolated from cultured podocytes; we used MRM
to measure the binding of sFLT1 to each of the 39 individual
ganglioside species (scheme in Figure 5B). This ‘‘lipidomic’’
approach identified GM3 as the predominant ganglioside spe-
cies in podocytes, which binds with significantly higher affinity
to sFLT1 than IgG controls. (Figures 5A and 5C; Table S2).
Further, we tested whether enzymatic removal of sialic residues
from gangliosides at the cell surface would affect cell binding to
sFLT1. We treated cells with neuraminidase that cleaves sialic
acid from the head group of the ganglioside and then performed
cell adhesion assays. Neuraminidase treatment results in greater
reduction of podocyte attachment to sFLT1 than to fibronectin
(61% versus 26%, respectively) (Figure 5D). These results sup-
port a role for GM3 in mediating sFLT1 binding to the podocyte
cell surface in the lipid rafts.
sFLT1 Binding Activates Intracellular Signaling
Pathways
The observation that, at 0C, sFLT1 binds to distinct membrane
microdomains suggests the preexistence of these membrane
entities independent of sFLT1 coalescence. However, the rapid
and dramatic effect of sFLT1 binding on the podocyte cyto-
skeleton suggests activation of specific intracellular signaling
pathways. Accordingly, we looked for transmembrane and intra-
cellular molecules that might lead to signaling in response to
sFLT1-induced raft dynamics.
The lipid raft-associated syndecan family of proteins is known
to relay extracellular matrix (ECM) cues to intracellular signaling
events that specifically regulate the actin cytoskeleton (Couch-
man, 2010; Morgan et al., 2007). Strikingly, syndecan 1 and 4
are localized to the exact membrane microdomains that bind
sFLT1 (Figures 6A and S3D; data not shown), except at the
cell-cell junctions that should be impermeable to exogenous
sFLT1. Syndecans are major transmembrane heparin sulfate
proteoglycans that play dual roles in ECM and cytoskeletal orga-
nization. Patching of sFLT1 induces rapid endocytosis of syn-
decan 1 (Figure S3D), reminiscent of endocytosis of ECM and
a5b1-integrin observed with syndecan 4 (Bass et al., 2011). In
addition to the coreceptor functions of the ectodomains, synde-
cans signal through their short cytoplasmic tails, recruiting
kinases and cytoskeletal regulatory proteins. Syndecans have
a short C-terminal EFYA motif that binds the PDZ domains of
cytoplasmic adaptor proteins (Figure 6B) andmediates a cooper-
ative interaction with the tandem PDZ domains of syntenin. This
interaction may couple syndecans to cytoskeletal targets and is
blocked by tyrosine phosphorylation of the syndecan EFYA
motif, thereby regulating actin dynamics (Grootjans et al.,
1997; Sulka et al., 2009). To determine if sFLT1-mediated clus-
tering of syndecans may be involved in regulating the cytoskel-
etal changes in podocytes following sFLT1 patching, we looked
for tyrosine phosphorylation changes within the EFYA motifs of
syndecan 1 and 4, using mass spectrometry. To overcome the
limitations of mass-spectrometry analysis of tryptic fragments
of phosphopeptides derived from the C-terminal end of proteins,
we designed a Lys-N-digestion-based mass spectrometry pro-
tocol. This allowed us to directly identify syndecan EFYA phos-phopeptides (Figures 6C, 6D, and S7). sFLT1 patching to the
surface of podocytes caused increased phosphorylation of
both syndecan 1 and 4 within their EFYA motifs, as judged by
mass spectrometry (MS) (Figures 6D and S7B). As anticipated,
phosphorylation of an EFYA-containing peptide from syndecan
1 blocks binding to the PDZ domains of syntenin (Figure 6E).
Furthermore, knockdown of syndecan 1 and 4 from podocytes
reduces adhesion of podocytes to sFLT1 (Figure 6G), but not
to fibronectin. Together, these data suggest that syndecans
may be among the transmembrane mediators of the actin
dynamics induced by sFLT1 patching.
Nephrin (encoded byNPHS1) is amember of the immunoglob-
ulin superfamily and constitutes a key component of a clinically
relevant pathway controlling podocyte actin dynamics. Clus-
tering of nephrin induces its tyrosine phosphorylation at three
sites that bind the SH2/SH3 adaptor protein Nck, which in turn
associates with actin regulators, such as N-Wasp (Blasutig
et al., 2008; Jones et al., 2006). Nephrin tyrosine phosphorylation
therefore leads to striking actin polymerization, important for the
formation of podocyte foot processes and maintenance of the
slit diaphragm. Moreover, nephrin is known to associate with
caveolin-1-containing lipid rafts in podocytes. Thus, we sought
to determine whether sFLT1 is involved in regulating phosphor-
ylation of nephrin.
We find that sFLT1 colocalizes with nephrin in a podocyte cell
line stably transfected with a plasmid expressing a MYC-tagged
nephrin (Figure S3D). Exposure of podocytes to sFLT1 induces
tyrosine phosphorylation of endogenous nephrin (Figure 6H),
as nephrin phosphorylation is clearly seen following patching
of sFLT1, while no phosphorylation is observed in an adjacent
cell that has not incorporated sFLT1. Despite similar morpho-
logic change, nephrin is not phosphorylated in podocytes fol-
lowing attachment to fibronectin (data not shown). To determine
the physiological relevance of these findings to the in vivo
setting, we examined expression of total and phosphorylated
nephrin in Nphs1-Cre+Flt1flox/flox mice. Nephrin tyrosine phos-
phorylation is lost at the onset of foot process effacement
in Nphs1-Cre+Flt1flox/flox mice, while total nephrin expression
remains unchanged (Figure 6I). Western blot analysis demon-
strates that dynamic sFLT1 binding to the cell surface correlates
with a time-dependent phosphorylation of nephrin (Figure 6J). A
model summarizing effects of sFLT1 patching on intracellular
signaling events in the podocyte is shown in Figure 6K.
sFLT1 Promotes Rapid Adhesion of Pericytes and
Perivascular Cells from Multiple Tissues
To investigate whether the functional properties of sFLT1 identi-
fied in podocytes are generalizable to pericytes from other
tissues, we performed adhesion assays in a number of pericyte
and perivascular cell lines, including placental pericytes, 10T1/
2 embryonic fibroblasts/pericytes, retinal pigment epithelial
(RPE) cells, and hepatic stellate cells (HSC). Similar to podo-
cytes, we found that each of these cell lines adhere to sFLT in
a heparin-dependent fashion (data not shown). Furthermore,
there was patching of sFLT1 to the surface of pericytes, recapit-
ulating the process we observed in podocytes (Figure 7A; data
not shown). Patching was most striking in embryonic 10T1/2
pericytes, RPEs (Figure 7A), and HSCs (data not shown). RPEsCell 151, 384–399, October 12, 2012 ª2012 Elsevier Inc. 389
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are perivascular cells with many similarities to podocytes,
including association with a fenestrated microvascular bed and
constitutive expression of VEGF. By contrast, the pattern of
patching was much weaker in primary glomerular endothelial
cells (data not shown) and human umbilical vein endothelial cells
(HUVECs) (Figure 7A) and dramatically different from podocytes,
suggesting a different role for sFLT1 in endothelium. In RPEs,
there was colocalization with syndecan 1 and 4 and internaliza-
tion of this transmembrane protein upon sFLT1 binding similar to
podocytes (data not shown), and neuraminidase treatment
reduces attachment of RPEs to sFLT1 (data not shown). While
our lipidomic analysis revealed some differences in surface
gangliosides in RPEs compared to podocytes, GM3 is the
predominant ganglioside type in both cells and binds to sFLT1
(data not shown).
FLT1 in Perivascular Cells Regulates Vascular Function
in Multiple Tissues
To determine if Flt1 is also required in perivascular cells and
pericytes outside the kidney to regulate vascular function, we
crossed the Flt1flox/flox mice to the Tcf21-Cre mouse strain.
Tcf21-Cre excises floxed alleles from embryonic mesenchymal
cells that give rise to pericytes, perivascular cells, and interstitial
cells in multiple tissues; these include podocytes, RPEs, HSCs,
and pericytes of the trachea, retina, and lung (Maezawa et al.,
2012). Importantly, this Cre-driver strain never excises from the
endothelium. In addition to proteinuria and podocyte defects
(data not shown), pericyte and vascular defects were also
observed in extrarenal tissues, including the retina, trachea,
lung, and liver. Mutant mice show increased vascularity and
excessive vascular sprouts in retinas and tracheas at 4 weeks
of age (Figures 7B and 7C). Excessive sprouting is associated
with reduced pericyte coverage and presence of pericytes with
abnormal morphology (Figure 7D).
DISCUSSION
Among the receptors for VEGF, the role of FLT1 is obscure.
Its signaling function is dispensable in development and its
soluble isoform, sFLT1, is best known as a decoy receptor that
inhibits the proangiogenic effects of VEGF. For example, ele-
vated circulating levels of sFLT1 are observed in patients withFigure 3. sFLT1 Promotes Cell Adhesion and Podocyte Cytoskeleton R
(A) Podocytes adhere to sFLT1 with a similar affinity as to fibronectin (FN). Podoc
optical density at 540 nm. Bars represent SEM.
(B) Adhesion to sFLT1 is dose dependent. Concentration of sFLT1 is shown on th
(C) Heparin abolishes adhesion to sFLT1 in a dose-dependent manner, but not to
represent SEM.
(D) Upon attachment to sFLT1 at 33C, human podocytes demonstrate dramatic
with cortactin (red), phalloidin (green), and DAPI (blue). No such change occu
podocytes when bound to sFLT1 is similar but not identical to alteration on fibro
(E) At 0C, sFLT1 is bound in a specific pattern to small patches on the podocyt
compact and discrete (white arrows).
(F) Immunogold EM demonstrates that binding of sFLT1 starts at ‘‘fluffy’’ discret
upper-left). At 33C, the sizes of labeled patches expand extensively, following
inside cells within membrane-encapsulated structures suggestive of endosomes (
between podocytes. sFLT1 can be observed filling the intercellular space (lower
See also Figures S1, S2, and S3 and Movie S1.pre-eclampsia, resulting in endothelial dysfunction in multiple
organs, including the glomerulus (Maynard et al., 2003). As
many of the features of pre-eclampsia, such as proteinuria and
hypertension, are recapitulated in patients who develop toxicity
following treatment with anti-VEGF antibodies and in transgenic
mouse models of VEGF knockdown, this decoy function of
sFLT1 is well supported (Eremina et al., 2008). However, the
role of sFLT1 in normal physiology is less clear. In healthy individ-
uals, circulating levels of sFLT1 are low, but sFLT1 can be found
localized to the extracellular matrix around healthy, fully differen-
tiated blood vessels, suggesting that it may play a role in normal
vascular biology (Sela et al., 2008).
Here we show that perivascular cells and pericytes that
support endothelial cells in various tissues produce sFLT1. Dele-
tion of Flt1 from one population of specialized pericytes, the
glomerular podocytes, in mice causes profound reorganization
of the podocyte actin cytoskeleton and proteinuria, reflecting
pericyte dysfunction. This proteinuria first manifests at 4 weeks
of age and increases rapidly, coincident with the normal kinetics
of sFlt1 expression by podocytes. The soluble isoform of Flt1
seems to be critical for these actions, as mice carrying a
kinase-deficient, truncated version of the Flt1 allele (Flt1TK/TK),
which is unable to signal in a conventional manner, have normal
kidneys and do not develop albuminuria. Furthermore, the Flt1TK
allele rescues the phenotype of Flt1-deficiency in podocytes,
underscoring the importance of the sFlt1 and/or transmembrane
portion of the molecule rather than Flt1 signaling in maintaining
normal podocyte function.
Although the embryonic development of podocytes is unaf-
fected in Nphs1-Cre+Flt1flox/flox mice, their podocyte foot pro-
cesses exhibit flattening by 5–6 weeks of age. Such dramatic
reorganization of foot processes, known as effacement, is ob-
served in primary and acquired proteinuric glomerular diseases.
Similar to patients with nephrotic syndrome, loss of normal foot
process structure in mice lacking Flt1 results in massive protein
leakage into the urine due to disruption of the glomerular perme-
ability barrier, resulting eventually in kidney failure.
How does loss of sFLT1 impact cytoskeletal regulatory path-
ways in pericytes? Given the profound defect in podocytes
without apparent abnormalities in other glomerular cell types,
we speculated that sFLT1 may function in an autocrine fashion
to modulate pericyte function. In keeping with this model, weeorganization and Is Rapidly Endocytosed
ytes do not adhere to sFLK1/KDR, PDGFRb, or IgG1 controls. O.D. represents
e x axis. *p < 0.01 from sFLT1 concentration at 0.0 mg/ml. Bars represent SEM.
fibronectin, suggesting a different mechanism of attachment. (*p < 0.01). Bars
morphologic change with extension of processes from the cell body, marked
rs when plated on sFLK1/KDR. Reorganization of the actin cytoskeleton of
nectin.
e cell surface. Upon thermoshifting to 33C (bottom), sFLT1 patches become
e patches on the podocyte cell surface (0C, arrowheads show gold particles,
the surface contour (upper-right). At this temperature, sFLT1 becomes visible
lower-left). Immunogold-labeled sFLT1 also appears at sites of cell-cell contact
-right). pm, plasma membrane; raft, putative lipid raft.
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Figure 4. sFLT1 Associates with the
Lipid Raft
(A) Cross-linking mass spectrometry protocol
designed to identify proteins that bind to sFLT1 on
the podocyte cell surface. Digestion with two
enzymes was performed with chymotrypsin or
trypsin.
(B) List of proteins for top peptide hits (defined by
MASCOT score) identified in cross-linking mass
spectrometry study. FLT1 had the highest score
followed by a number of candidate membrane-
associated proteins. See also Figure S3D.
(C) Isolation of detergent-resistant fraction from
podocytes demonstrates that sFLT1 is localized to
the lipid raft along with SCARB1 and caveolin-1.
Integrinb3 marks the nonraft component.
(D) sFLT1 extensively colocalizes with the CTxB
that marks the lipid raft. Areas of sFLT1 (in green)
and CTxB (in red) are indicated by varying shades
of the yellow-orange composite color, which
appear extensive (see close-up).
(E) Distribution and pattern of CTxB and sFLT1
binding is dramatically altered in ANXA2 knock-
down podocytes, as CTxB rafts and sFLT1 are
absent from the center area of cells (above the
nucleus) as compared to controls (compare E to
D). Top panels show sFLT1 patching at 0C and
bottom panels show patching at 33C. See also
Figure S4C and S4E.
See also Figures S3D and S4 and Movie S1.observed dynamic patching and endocytosis of sFLT1 followed
by rapid morphologic change of podocytes exposed to sFLT1,
suggesting that sFLT1 binds to cell surface molecules. Utilizing
a proteomics approach followed by colocalization studies, we
identified a number of proteins that associate with sFLT1 at the
cell surface. Intriguingly, two of the top hits, SCARB1 and
ANXA2, are proteins known to associate with lipid rafts—subdo-
mains involved in podocyte actin dynamics and in cytoskeletal
reorganization in other pericyte populations (Simons et al.,
2001; Sundberg et al., 2009). Along with their location in lipid
rafts, these proteins were of interest for other reasons. First,392 Cell 151, 384–399, October 12, 2012 ª2012 Elsevier Inc.SCARB1 is a scavenger receptor that
binds molecules, such as apolipopro-
teins, facilitating their endocytosis. In
addition, mutations in another member
of the SCARB family, SCARB2, are
associated with proteinuric glomerular
disease and podocyte structural defects,
although the mechanism(s) is not known
(Balreira et al., 2008; Berkovic et al.,
2008). ANXA2 controls actin cytoskeleton
dynamics functioning as an actin-
capping and actin monomer-binding
protein in nonrenal cell types, including
gut epithelium, where it regulates
pedestal formation following insertion of
the E. coli EPEC/Tir proteins; this process
is highly analogous to nephrin-mediated
foot process formation (Blasutig et al.,2008; Hayes et al., 2006; Zobiack et al., 2002). While we
were unable to show direct interactions between sFLT1 and
SCARB1 or ANXA2, we reasoned that their colocalization may
reflect an association in the same molecular complex at the
cell surface.
In support of this model, we showed that sFLT1 colocalizes
with cholera toxin B and is present in the detergent-resistant
membrane fraction together with SCARB1, arguing that sFLT1
binds to lipid rafts. We also showed that sFLT1 binds directly
to the glycosphingolipid ganglioside GM3, a highly enriched
component of lipid rafts that binds to a variety of growth factor
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receptors, facilitating signal transduction in other cells, such as
T cells (Regina Todeschini and Hakomori, 2008).
Although it is not possible to genetically alter a single gangli-
oside in isolation, due to common steps in their synthesis,
mutations in the major sialic acid biosynthesis enzyme Gne,
which is required for proper GM3 synthesis, results in a
profound glomerular defect and proteinuria in mice (Galeano
et al., 2007), and reduced glomerular expression of the GM3
ganglioside has been linked to proteinuric kidney disease
(Kwak et al., 2003). In this paper we demonstrate that GM3 is
the most abundant ganglioside in podocytes and that removal
of sialic acid residues with neuraminidase inhibits podocyte
adhesion to sFLT1. These data support a functional role for
GM3 in the filtration barrier and specifically in podocyte
function.
There are several possible mechanisms governing the inter-
actions between sFLT1 and GM3 in the lipid raft. The first is
through direct carbohydrate-carbohydrate interactions, as has
been reported for GM3 and EGFR (Yoon et al., 2006). In addition,
we speculate that opposing electrostatic potentials between
sFLT1 and GM3 may contribute to binding (Figures S5A and
S5B). A sialic acid moiety constitutes the polar head of all gangli-
osides, including GM3, providing a negative charge (Figure S5B)
and raising the possibility that sFLT1 may bind to other ganglio-
sides present in the lipid raft. Similar to GM3, heparin also
possesses a highly negative charge density (Figure S5C) and is
known to bind to extracellular domains of VEGF receptors,
including sFLT1 (Olsson et al., 2006; Park and Lee, 1999). It is
plausible that heparin blocks sFLT1-mediated adhesion and
raft clustering through charge interference with the sFLT1-GM3
interaction.
Howmight binding to the lipid raft result in changes in the actin
cytoskeleton? Lipid rafts are highly dynamic domains within the
cell membrane. Extracellular proteins that bind to these domains
can promote coalescence or ‘‘pooling’’ of lipid-raft associated
proteins into larger assemblies, allowing interactions to occur
between signaling molecules that result in activation of spe-
cific intracellular signaling pathways (Figure 6K). Live imaging
of podocytes showed rapid fusion of sFLT1 patches on the
podocyte cell surface consistent with pooling of microdo-
mains. Furthermore, binding of sFLT1 to the lipid raft causes
striking morphologic changes and protrusion of foot process-
like extensions from the podocyte cell body coincident with
activation of intracellular signaling events that include nephrin
phosphorylation.Figure 5. Lipidomic Screen Using Mass Spectrometry Reveals sFLT1 B
(A) (Left) MS/MS spectrum of a GM3 standard (extracted from brain)—the red d
transition m/z 290.0 that, with the 1179.9 m/z parent ion, was used to build theMR
20-fold higher affinity than to IgG control as measured by MRM assay (right).
(B) Workflow for ganglioside extraction from cultured podocytes followed by mea
to monitor 39 ganglioside species copurified with sFLT1 and IgG. Examples o
magnified (insert) to show levels.
(C) Twenty-two out of the 32 observed gangliosides from podocytes that showe
intensity levels from four experimental repeats). The top three hits are all GM3 sp
Bars represent SD.
(D) Treatment of podocytes with H1N1 neuraminidase reduces the level of cell at
experiments). Bars represent SEM.
See also Figures S5 and S6 and Table S2.
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might relay sFLT1-induced lipid raft dynamics to intracellular
responses, we found members of the syndecan family of hep-
aran sulfate proteoglycans, namely syndecan 1 and 4, are local-
ized to the samemembrane microdomains (Figures 6A and S3D;
data not shown). Moreover, sFLT1 patching promotes coales-
cence and subsequent internalization of syndecan 1 and 4 (Fig-
ure S3D; data not shown) in a fashion similar to ECM-regulated
cellular actions that occur through syndecan 4 (Bass et al.,
2011), suggestive of a coclustering mechanism. The intracellular
domain of syndecan is known to recruit signaling molecules,
such as PKCa, and activate Src and focal adhesion kinase
(FAK) tyrosine kinases upon ECM engagement (Couchman,
2010; Morgan et al., 2007). Thus, sFLT1 coalescence at the
cell surface may cause the activation of Src and FAK pathways
directly through syndecan, and this leads to the phosphorylation
of nephrin in podocytes (Verma et al., 2006). Indeed, we show
that phosphorylation of Tyr309 of syndecan 1 and Tyr197 of
syndecan 4 are both increased upon sFLT1 patching (Figures
6D and S7). EFYA motifs of syndecans are known to recruit
the PDZ domains of proteins that modulate intracellular signal-
ing and cytoskeletal responses, and this binding is abrogated
following syndecan phosphorylation (Sulka et al., 2009). We
hypothesize that clustering of syndecans followed by phosphor-
ylation of their EFYA motifs is a mechanism by which sFLT1
patching relays signals to induce cellular changes.
We find that sFLT1 is produced by other perivascular cell
types, and attachment to sFLT1 is a general characteristic of
pericytes from diverse lineages. Destabilization of pericyte-
endothelial interactions, which is a prerequisite for sprout-
ing angiogenesis, requires alteration of the cytoskeleton of
perivascular cells and alterations in adhesion to underlying
basement membrane. Our findings suggest that sFLT1 may
be one pathway linking these two processes. In support of
this model, deletion of FLT1 from extraglomerular pericytes
and perivascular cells results in excessive sprouting angiogen-
esis in the retina and trachea and disrupted vasculature in mul-
tiple tissues.
In summary, our studies show that sFLT1 produced by peri-
cytes has powerful autocrine functions to control cytoskeletal
dynamics affecting their functions; elimination of FLT1 produc-
tion by glomerular podocytes is sufficient to cause structural
abnormalities, including effacement and loss of integrity of the
glomerular barrier. We suggest that these functions are more
broadly applicable to other specialized pericyte populationsinding Predominately to GM3 Ganglioside
otted line to the structural formula indicates fragmentation for production of
M assay for quantitative mass spectrometry (middle). GM3 binds to sFLT1 with
surement of affinities to sFLT1 by mass spectrometry. MRM was programmed
f obtained spectra are shown at the bottom. Lower affinity gangliosides are
d enrichment and differential binding to sFLT1 are plotted (ranked by average
ecies, suggesting GM3 is the predominant ganglioside interacting with sFLT1.
tachment to sFLT1-coated surfaces. (*p < 0.05; ***p < 0.01, n = 5 independent
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and perivascular cells in mature vascular beds. Our findings
suggest a paradigm for organization of the pericyte cytoskeleton
that will be relevant to vascular biology and disease.
EXPERIMENTAL PROCEDURES
Transgenic Mice
Floxed Flt1 and Flt1 tyrosine kinase deficient (Flt1TK/TK) mice have been
described (Ambati et al., 2006; Hiratsuka et al., 1998). Cre driver strains
used were: Nphs1-Cre (Eremina et al., 2002) and Tcf21- (Maezawa et al.,
2012). See additional details in Extended Experimental Procedures.
Urine and Histologic Analysis
Details are provided in Extended Experimental Procedures.
Immunohistochemistry
Primary and secondary antibodies used on cells and tissue sections, together
with detailed staining protocols, are provided in Extended Experimental
Procedures.
FACS Sorting of Primary Podocytes
Glomeruli were isolated from 1-, 3-, and 6-week-old Nphs1–cyan fluorescent
protein (CFP) transgenic mice by the sieving method (n = 3–5 mice in each
age group). CFP-expressing podocytes were dissociated and separated by
FACS analysis as previously described (Sison et al., 2010).
sFLT1 Patching Assay
Podocytes, RPEs, 10T1/2 cells, and HUVECs were grown on glass cover-
slips; binding of sFLT1 to the cell surface was allowed to proceed for 30 min
at indicated temperature. Cells were fixed, permeabilized, blocked, and
stained with indicated reagents following standard sample preparation
protocol for immunofluorescence studies. VEGF, blocking studies, antibody
details, and immunotransmission EM details are in Extended Experimental
Procedures.
Crosslinking and Mass Spectrometry
Confluent podocytes grown in 500 cm2 plates were incubated with either
sFLT1-Fc recombinant protein or human IgG control antibody. After washing,
BS3 at 0.1 mM in phosphate buffer was added to the cells and the crosslinking
reaction was allowed to proceed for 10 min. Total cell lysates were then
collected and extracted with protein A- and protein G-sepharose beads
to purify sFLT1-Fc together with crosslinked binding proteins. Details of
sample preparation, mass spectrometry analysis, and scoring are provided
in Extended Experimental Procedures.Figure 6. sFLT1 Binding Activates Intracellular Signaling Pathways
(A) sFLT1 binding to microdomains on the surface of podocytes that are marked
(B) A working model to show sFLT1 patching induces phosphorylation of the cons
though recruitment of PDZ domain-containing proteins.
(C) Hemagglutinin (HA)-tagged syndecan 1was purified from podocytes that were
spectrometry (also in D). The resolving MS-MS spectrum map of a phospho-KQE
b-series (highlighted in red) and y-series ions (not highlighted).
(D) MRM assay quantifies the levels of phospho-Tyr309 (compare peak intensity
(E) Top panel: Synthetic syndecan 1 peptide containing the C-terminal EFYAmotif
does not bind syntenin. The bottom panel shows the expression of the syntenin
(F) Syndecan knockdown in podocytes reduces syndecan 1 and 4 expression in
(G) Syndecan knockdown reduces podocyte adhesion to sFLT1, but not to FN in
(H) Phosphorylation of endogenous nephrin seen in a podocyte following patching
has a lower level of sFLT1 incorporation (cell on the right).
(I) Nephrin phosphorylation is decreased in Nphs1-Cre+Flt1flox/flox mice at the on
(J) Western blot analysis shows time-dependent increase in nephrin phosphoryla
(K) Hypothetical model to illustrate autocrine function of sFLT1 to regulate podoc
contain nephrin, podocin, syndecan, and other raft proteins, such as SCARB1 and
lipid raft, resulting in coalescence and phosphorylation of syndecans and nephri
See also Figure S7.
396 Cell 151, 384–399, October 12, 2012 ª2012 Elsevier Inc.Affinity between sFLT1 and GM3 Ganglioside Measured by Mass
Spectrometry
GM1, GM3, and GD1a ganglioside standards were incubated for 1 hr with
protein A/G-sepharose beads that had been preabsorbed with either sFLT1-
Fc or control human IgG. After extensive washes, GM3 bound to the beads
was extracted with methanol and the GM3 assay was run on an liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS) system (additional details
in Extended Experimental Procedures).
LC-MRM Analysis of Gangliosides
The GM3 assay was developed and run on a nano LC-MS/MS system (details
in Extended Experimental Procedures). Global ganglioside profiling was devel-
oped and run on a normal LC-MS/MS system, consisting of an Agilent 1100
cap LC system and a 4000 QTRAP mass spectrometer (AB SCIEX, Toronto,
Canada). Samples were loaded and separated on a TSK-Gel Amide 80 column
(4.6 mm ID 3 25 cm, 3 mm, Tosoh Bioscience, Montgomeryville, PA). The
multiple reaction monitoring (MRM) assay was programmed with 39 ganglio-
side precursor ions and the most abundant ion product of sialic acid  m/z
290.0 (sialic acid minus a water molecule), according to previous report
(Ikeda and Taguchi, 2010). Additional details are in Extended Experimental
Procedures.
Syndecan Phosphorylation Studies Using Mass Spectrometry
The method to identify and quantify syndecan phosphorylation were adapted
from a previous study (Bisson et al., 2011). Additional details, such as sample
preparation and a Lys-N-based mass spectrometry protocol to detect and
quantify C-terminal phosphorylation of syndecan 1 and 4, are provided in
Extended Experimental Procedures. The assay on recombinant syntenin
PDZ domain binding to peptides derived from the C-terminal sequences of
syndecan 1 and 4 is also described in Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, two tables, and one movie and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2012.08.037.
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